
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
“安斯泰来(Astellas)”的名称衍生自希腊语词汇“aster”、拉丁语词汇“stella”和英语词汇“stellar”,都是“天上繁星”之意。...
2021年11月9日,安斯泰来制药(中国)有限公司(以下简称“安斯泰来”)与青岛百洋医药股份有限公司(以下简称“百洋医药”)在青岛签署合作协
2021年11月8日,中国,北京...
*本文来源于《医药代表》公众号对安斯泰来大中华商业总经理滨口洋先生的独家专访,全文如下:...
- Enfortumab vedotin是日本首个也是唯一一个获准用于治疗患有晚期尿路上皮癌患者的抗体偶联药物(ADC) 2021年9月27日,东京和华盛顿州波士尔市 -...
Read more about 日本厚生劳动省批准将PADCEV®(enfortumab vedotin)用于治疗晚期尿路上皮癌
